Vanda Pharmaceuticals Shares Are Trading Higher After the US Supreme Court Reportedly Declined to Hear the Company's Case Regarding the Invalidation of Patents for Hetlioz.
Vanda Pharmaceuticals Shares Are Trading Higher After the US Supreme Court Reportedly Declined to Hear the Company's Case Regarding the Invalidation of Patents for Hetlioz.
據報道，美國最高法院拒絕審理該公司有關Hetlioz專利無效的案件，此後，萬達製藥股價走高。
Vanda Pharmaceuticals Shares Are Trading Higher After the US Supreme Court Reportedly Declined to Hear the Company's Case Regarding the Invalidation of Patents for Hetlioz.
據報道，美國最高法院拒絕審理該公司有關Hetlioz專利無效的案件，此後，萬達製藥股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。